← Leaderboards
Emese Zsiros
Roswell Park Cancer Institute Corp
$1,300,628
Attributed
$2,601,255
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $693.9K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,601,255 · 1
By mechanism
R01$2,601,255 · 1
Top collaborators
- Brahm H. Segal4 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Scott I. Abrams$11,133,748
- Kathryn L Lunetta$12,857,453
- Leigh Ellis$3,518,676
- Xiang-Yang Wang$11,998,946
- Pawel Kalinski$15,491,276
Others in their field
Other Rising Stars on “Diagnosis”
- David Annett · Information Management Services, Inc.$35,571,865
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Jennifer Lee O'Brien · University Of South Florida$15,110,862
- Daniel Hunter Reirden · Westat, Inc.$15,038,020
- Thomas K Karikari · Wake Forest University Health Sciences$14,340,584
- John Alam · Eip Pharma, Inc.$10,411,018
Research focus
DiagnosisDisorder ControlCytotoxic T-LymphocytesAnaphylatoxinsBevacizumabBiologyCytometryAscitesBlood VesselsCancer ImmunotherapyCancer PatientCause Of DeathCell InjuryChemokineChemotactic FactorsBloodCohortComplementComplement 3aComplement 5aComplement Component C4aCyclophosphamideCytokineDisseminated Malignant Neoplasm
Grant awards (4)
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$642,760
R01 · FY2025 · CA · contact PI
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$618,854
R01 · FY2024 · CA · contact PI
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$645,738
R01 · FY2023 · CA · contact PI
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer$693,903
R01 · FY2022 · CA · contact PI